HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor

Blood

Volumn 87, Issue 9, 1996, Pages 3803-3812

  Elsässer, David ^b   Valerius, Thomas ^a   Repp, Roland ^b   Weiner, George J ^b   Deo, Yashwant ^b   Kalden, Joachim R ^b   Van De Winkel, Jan G J ^b   Stevenson, George T ^b   Glennie, Martin J ^b   Gramatzki, Martin ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CYTOLYSIS; DRUG EFFECT; DRUG MIXTURE; DRUG SCREENING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL;

EID: 0345365618     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3803.bloodjournal8793803     Document Type: Article

References (53)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma N Engl J Med 328:1023, 1993
2. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
3. Lieschke GJ, Burgess AW: Drug therapy: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (I + II). N Engl J Med 327:28 and 99, 1992
4. Platzer E, Weite K, Gabrilove JL, Lu L, Harris P, Mertelsmann R, Moore MAS: Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 162:1788, 1985
5. Lichtenstein A: Granulocytes as possible effectors of tumor immunity, in Oettgen HF (ed): Human Cancer Immunology I. Philadelphia, PA, Saunders, 1990, p 731
6. Cemerlic D, Dadey B, Han T, Vaickus L: Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes. Blood 77:2707, 1991
7. van de Winkel JGJ, Capel PJA: Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol Today 14:215, 1993
8. Fanger MW, Shen L, Graziano RF, Guyre PM: Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 10:92, 1989
9. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E: Neutrophils express the high affinity receptor for IgG (Fc-gamma RI; CD64) after in vivo application of rhG-CSF. Blood 78:885, 1991
10. Valerius T, Repp R, de Wit TPM, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JGJ: Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931, 1993
11. Kerst JM, de Haas M, van der School E, Slaper-Cortenbach ICM, Kleijer M, von dem Borne AEGK, van Oers RHJ: Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: Induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82:3265, 1993
12. Fanger MW, Morganelli PM, Guyre PM: Bispecific antibodies. Crit Rev Immunol 12:101, 1992
13. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW: Phase Ia/Ib trial of bispecific antibody MDX-210 (anti-HER-2/neu X anti-FcγRI) in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281, 1995
14. Maca RD, Bonnard GD, Herberman RB: The suppression of mitogen- and alloantigen-stimulated peripheral blood lymphocytes by cultured human T lymphocytes. J Immunol 123:246, 1979
15. Klein G, Lindahl T, Jondal M, Leibold W, Menezes J, Nilsson K, Sundström C: Continuous lymphoid cell lines with characteristics of B cells (bone marrow derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci USA 71:3283, 1974
16. Lampson LA, Levy R: Two populations of Ia-like molecules on a human B-cell line. J Immunol 125:293, 1980
17. Epstein AL, Marder R, Winer JN, Stathopoulos E, Chen FM, Parker JW, Tyalor CR: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47:830, 1987
18. Gingrich RD, Dahle CE, Hoskins KF, Senneff MJ: Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 75:2375, 1990
19. de Rie MA, Schumacher TNM, van Schijndel GMW, van Lier RAW, Miedema F: Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol 118:368, 1989
20. Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA: CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 138:2793, 1987
21. Campana D, Janossy G, Bofill M, Trejdosiewicz LK, Ma D, Hoffbrand AV, Lebacq AM, Forster HK: Human B cell development I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol 134:1524, 1985
22. Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G: The B cell-associated CD37 antigen (gp40-52): Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140:905, 1988
23. Moore K, Cooper SA, Jones DB: Use of the monoclonal antibody WR17, identifying the CD37 gp40-45Kd antigen complex, in the diagnosis of B lymphoid malignancy. J Pathol 152:13, 1987
24. Ellis JH, Barber KA, Tutt AL, Hale C, Lewis AP, Glennie MJ, Stevenson GT, Crowe JS: Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 155:925, 1995
25. Gosselin EJ, Wardwell K, Rigby WFC, Guyre PM: Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-γ, and IL-3. J Immunol 151:1482, 1993
26. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW: Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143:1650, 1989
27. Looney RJ, Abraham GN, Anderson CL: Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641, 1986
28. Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fcγ receptor distribution and structure Proc Natl Acad Sci USA 79:3275, 1982
29. Greenman J, Tutt AL, George AJT, Pulford KAF, Stevenson GT, Glennie MJ: Characterization of a new monoclonal antibody, AT10, and its incorporation into a bispecific F(ab′)2 derivate for recruitment of cytotoxic effectors. Mol Immunol 28:1243, 1991
30. Stevenson GT, Glennie MJ, Kan KS: Chemically engineered chimeric and multi-Fab antibodies, in Clark M (ed): Protein Engineering of Antibody Molecules. Nottingham, UK, Academic Titles, 1993, p 127
31. 3 antibody derivates, in Gallagher G, Rees RC, Reynolds CW (eds): Tumour Immunobiology, a Practical Approach. Oxford, UK, Oxford University Press, 1995, p 225
32. Elliot TJ, Glennie MJ, McBride H, Stevenson GT: Analysis of the interaction of antibodies with immunoglobulin idiotypes of neoplastic B lymphocytes: Implications for immunotherapy. J Immunol 138:981, 1987
33. Valerius T, Repp R, Kalden JR, Platzer E: Effects of IFN on human eosinophils in comparison with other cytokines: A novel class of eosinophil activators with delayed onset of action. J Immunol 145:2950, 1990
34. Graziano RF, Fanger MW: Human monocyte-mediated cytotoxicity: The use of Ig-bearing hybridomas as target cells to detect trigger molecules on the monocyte cell surface. J Immunol 138:945, 1987
35. Dearman RJ, Stevenson FK, Wrightham M, Hamblin TJ, Glennie MJ, Stevenson GT: Lymphokine-activated killer cells from normal and lymphoma subjects are cytotoxic for cells coated with antibody derivatives displaying human Fcγ. Blood 72:1985, 1988
36. Bridges SH, Kruisbeek AM, Longo DL: Selective in vivo antitumor effects of monoclonal anti-I-A antibody on a B cell lymphoma. J Immunol 139:4242, 1987
37. Vaickus L, Jones VE, Morton CL, Whitford K, Bacon RN: Antiproliferative mechanism of anti-class II monoclonal antibodies. Cell Immunol 119:445, 1989
38. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ: Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83:2787, 1994
39. Scott DW, Livnat D, Pennell CA, Keng P: Lymphoma models for B cell activation and tolerance. III. Cell cycle dependence for negative signalling of WEHI-231 B lymphoma cells by anti-μ. J Exp Med 164:156, 1986
40. Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der Schoot CE, von dem Borne AEGK, Slaper-Kortenbach ICM: Fcγ receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood 83:1632, 1994
41. Schroff RW, Farrell MM, Klein RA, Stevenson HC, Warner NL: Induction and enhancement by monocytes of antibody-induced modulation of a variety of human lymphoid cell surface antigens. Blood 66:620, 1985
42. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906, 1989
43. Cambier JC, Pleiman CM, Clark MR: Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol 12:457, 1994
44. Scholl PR, Geha RS: MHC class II signaling in B-cell activation. Immunol Today 15:418, 1994
45. Altomonte M, Pucillo C, Damante G, Maio M: Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-α by the EBV-B lymphoblastoid cell line JY. J Immunol 151:5115, 1993
46. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G: Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173:889, 1991
47. Midorikawa Y, Yamashita T, Sendo F: Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: Abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res 50:6243, 1990
48. Matsumoto Y, Saiki I, Murata J, Okuyama H, Tamura M, Azuma I: Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice. Int J Cancer 49:444, 1991
49. Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, van de Winkel JGJ, Lang N, Kalden JR: G-CSF stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcγRI and to HER-2/neu (MDX210). J Hematotherapy 4:415, 1995
50. Hu E, Epstein AL, Naeve GS, Gill I, Martin S, Sherrod A, Nichols P, Chen D, Mazumder A, Levine AM: A phase Ia clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155, 1989
51. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF: Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425, 1994
52. Brissinck J, Demanet C, Moser M, Leo O, Thielemans K: Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147:4019, 1991
53. Weiner GJ, Hillstrom JR: Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147:4035, 1991